Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study.

Yoshiteru TakekitaShuichi HiraokaYasuhiro IwamaNaotaka SunadaNobuatsu AokiHaruhiko OgataToshiya FunatsukiChikashi TakanoTomoyo YanagidaYosuke KoshikawaMinami NaitoAtsuko YamamotoMasaki KatoToshihiko Kinoshita

Published in: CNS spectrums (2021)

The efficacy and safety of asenapine 10 and 20 mg/day differed between the 3 clusters of patients. This suggests that background information regarding baseline psychiatric symptoms may affect the therapeutic response in patients with schizophrenia.

Keyphrases

double blind
placebo controlled
phase iii
end stage renal disease
clinical trial
newly diagnosed
ejection fraction
chronic kidney disease
open label
mental health
prognostic factors
randomized controlled trial
healthcare
physical activity
patient reported outcomes
social media